Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75%
Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME REDWOOD CITY, Calif., April 15, 2025 — Ashvattha Therapeutics (“Ashvattha”),
New Clinical Advisory Board brings together distinguished retinal specialists to provide strategic guidance on development of Ashvattha’s innovative nanomedicine programs REDWOOD CITY, Calif., Mar. 18,
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue
Ashvattha receives additional financing up to $50 million with new lead investor Tribe Capital and existing investors led by Natural Capital Ashvattha’s at-home monthly subcutaneously-administered
Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the
Presentations highlight the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE
The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral
REDWOOD CITY, Calif., February 14, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively